Around 125 million people worldwide have psoriasis, the skin condition that causes flaky patches on the surface to form as scales. In the UK, the NHS estimates that two in 100 people suffer, with ...

Whether you suffer from psoriasis yourself or have heard about it from a famous Kardashian who has been very transparent about her symptoms, you know that the skin condition is far from glamorous and ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window An ...

Two years ago, Dermavant forked over £150 million ($198 million) upfront to get its hands on GlaxoSmithKline’s phase 3-ready psoriasis cream. Now, with positive phase 3 data in hand, the company is ...

Please provide your email address to receive an email when new articles are posted on . Arcutis Biotherapeutics announced positive results from two pivotal phase 3 studies evaluating Zoryve cream as a ...

Finding a cream that actually helps with psoriasis can make a real difference. Whether your skin is inflamed, sensitive, or just uncomfortable, the right skincare product can calm irritation and leave ...

A PDUFA target date of June 29, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for roflumilast cream 0.3% for ...

Vtama (tapinarof), the first new topical psoriasis drug to get the agency’s okay in 25 years, is set to launch in early June. On May 24, the U.S. Food and Drug Administration (FDA) approved Vtama ...

Hot off its first approval this summer in psoriasis, Arcutis Biotherapeutics’ roflumilast foam 0.3%, approved in cream form under the brand name Zoryve, is out to prove it’s no one-trick pony in itch.

- 88.5% of adult patients achieved a target lesion Physician Global Assessment (tPGA) score of 0 (clear) or 1 (almost clear) and ≥ 2-grade improvement from baseline at Week 12 (tPGA Success), ...

A cream medication that eases skin inflammation might offer a safer treatment option for people with psoriasis, a new clinical trial suggests. Psoriasis is a chronic skin condition that affects more ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. 82.8% of patients treated with Vtama achieved the ...